Enliven Therapeutics, Inc. ELVN

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in the following investor conferences:

Miners like Southern Copper and Newmont lead this screen of stocks to watch in or near buy range alongside UBS, Garmin and more.

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that the Company will present data from the ENABLE Phase 1 clinical trial of ELVN-001 in an oral and a poster presentation at the Society of Hematologic Oncology (SOHO) Annual Meeting, taking place September 9-12, 2026, at the George R. Brown Convention Center in Houston, Texas. This is an encore pr

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the second quarter ended June 30, 2026, and provided a business update.

AI stocks have come under heavy selling pressure in the stock market, but biotechs are still catching a bid among institutional investors.

Plus, other significant moves in holdings of Oruka Therapeutics, Enliven Therapeutics, NN, and Alvotech.

A barrage of stocks to watch like Eli Lilly and Deere, show promise, alongside reminders to keep risk management in mind.

Enliven Therapeutics has raced ahead with a 220.6% year to date return, yet the broader valuation checks and market multiples now lean toward the stock looking expensive rather than like an obvious bargain. The year to date gain of 220.6% suggests expectations around Enliven Therapeutics have reset significantly higher and leaves less room for disappointment. Upcoming work on the ENABLE-2 Phase 3 trial for ELVN-001 can support long term value if progress continues as planned, while recent...

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has closed its upsized underwritten public offering of 10,533,334 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,600,000 additional shares of its common stock, at a price to the public of $37.50 per share and, in lieu of common stock to

Enliven Therapeutics Inc. (NASDAQ:ELVN) is one of the 10 Stocks That Absolutely Exploded Higher. Enliven Therapeutics rallied for a fourth consecutive day on Friday, climbing 14.30 percent to finish at $46.13 apiece, as investor sentiment was bolstered by the encouraging results from its experimental leukemia drug, ELVN-001. In an updated report, Enliven Therapeutics Inc. (NASDAQ:ELVN) […]

As of March 2026, ELVN-001 produced meaningful responses in heavily pretreated patients, many of whom had already tried multiple existing therapies, Enliven Therapeutics said.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2% and the actively trad

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has priced its previously announced upsized underwritten public offering of 8,933,334 shares of its common stock at a price to the public of $37.50 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase up to 1,733,333 shares of Enliven's common st

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase shares of Enliven's common stock. In addition, Enliven intends to grant the underwriters a 30-day option to p